Charles Bennett to Medicare
This is a "connection" page, showing publications Charles Bennett has written about Medicare.
Connection Strength
1.005
-
Medicare Spending on Drugs With Accelerated Approval. Ann Intern Med. 2022 07; 175(7):938-944.
Score: 0.167
-
The First 2?Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. Oncologist. 2021 08; 26(8):e1418-e1426.
Score: 0.153
-
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000 Aug; 18(15):2805-10.
Score: 0.147
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.132
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.117
-
The excessive cost of early stage bladder cancer care: are providers really to blame? Cancer. 2010 Aug 01; 116(15):3530-2.
Score: 0.074
-
Cost considerations in the management of cancer in the older patient. Oncology (Williston Park). 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim.
Score: 0.059
-
The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol. 2004 May-Jun; 2(3):271-8.
Score: 0.048
-
Diffusion of laparoscopic cholecystectomy in the Veterans Affairs health care system, 1991-1995. Eff Clin Pract. 1999 Mar-Apr; 2(2):49-55.
Score: 0.033
-
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
Score: 0.033
-
Assessing Colorectal Cancer Screening Adherence of Medicare Fee-for-Service Beneficiaries Age 76 to 95 Years. J Oncol Pract. 2016 06; 12(6):e670-80.
Score: 0.027
-
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007 Feb 07; 99(3):196-205.
Score: 0.014